{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T13:29:08Z","timestamp":1795181348678,"version":"4.10.3"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-63091-0","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:39:27Z","timestamp":1755614367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-9105","authenticated-orcid":false,"given":"Amin H.","family":"Nassar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolulope","family":"Adeyelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0063-0518","authenticated-orcid":false,"given":"Elias","family":"Bou Farhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Abushukair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-0153","authenticated-orcid":false,"given":"Mehrdad","family":"Rakaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Matteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-3205","authenticated-orcid":false,"given":"Shun-Fat","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamato","family":"Takabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0664-2376","authenticated-orcid":false,"given":"Antonio","family":"Ocejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Ardeshir-Larijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticiana","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0757-3106","authenticated-orcid":false,"given":"Suresh","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaiya","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-7062","authenticated-orcid":false,"given":"Jhanelle E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kaldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Baena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Zurera","family":"Berjaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Aboubakar","family":"Nana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Grohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Leuders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3096-4452","authenticated-orcid":false,"given":"Fabrizio","family":"Citarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1209-5735","authenticated-orcid":false,"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2918-7693","authenticated-orcid":false,"given":"Emanuele Claudio","family":"Mingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Pancirer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3217-8335","authenticated-orcid":false,"given":"Timothy John","family":"Ellis-Caleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8139-3322","authenticated-orcid":false,"given":"Arthi","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-3912","authenticated-orcid":false,"given":"Fionnuala","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5903-8191","authenticated-orcid":false,"given":"Thomas U.","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanya","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtaza","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamya","family":"Sankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Kawtharany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-6187","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight H.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Awosika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Alhamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unaiza","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya M.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-5557","authenticated-orcid":false,"given":"Ana I.","family":"Velazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyiesha","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-242X","authenticated-orcid":false,"given":"Laura","family":"Moliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-3184","authenticated-orcid":false,"given":"Miguel","family":"Mosteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6842-2563","authenticated-orcid":false,"given":"Ari","family":"Vanderwalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8031","authenticated-orcid":false,"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1605-4719","authenticated-orcid":false,"given":"Jorge","family":"Nieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-4454","authenticated-orcid":false,"given":"Hossein","family":"Borghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raid","family":"Aljumaily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-5847","authenticated-orcid":false,"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0778","authenticated-orcid":false,"given":"Richard A.","family":"Flavell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafeh","family":"Naqash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2111-4694","authenticated-orcid":false,"given":"Anne C.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"63091_CR1","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis, W. D. et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J. Thorac. Oncol. 10, 1243\u20131260 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"63091_CR2","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.cllc.2016.01.003","volume":"17","author":"J Naidoo","year":"2016","unstructured":"Naidoo, J. et al. Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes. Clin. Lung Cancer 17, e121\u2013e129 (2016).","journal-title":"Clin. Lung Cancer"},{"key":"63091_CR3","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","volume":"22","author":"N Rekhtman","year":"2016","unstructured":"Rekhtman, N. et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin. Cancer Res. 22, 3618\u20133629 (2016).","journal-title":"Clin. Cancer Res."},{"key":"63091_CR4","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(04)15693-6","volume":"363","author":"MH Jones","year":"2004","unstructured":"Jones, M. H. et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363, 775\u2013781 (2004).","journal-title":"Lancet"},{"key":"63091_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/his.12278","volume":"64","author":"MF Bari","year":"2014","unstructured":"Bari, M. F. et al. BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas. Histopathology 64, 547\u2013556 (2014).","journal-title":"Histopathology"},{"key":"63091_CR6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/path.4853","volume":"241","author":"M Simbolo","year":"2017","unstructured":"Simbolo, M. et al. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. J. Pathol. 241, 488\u2013500 (2017).","journal-title":"J. Pathol."},{"key":"63091_CR7","doi-asserted-by":"publisher","first-page":"e819","DOI":"10.1200\/JCO.2011.36.2251","volume":"29","author":"TM De Pas","year":"2011","unstructured":"De Pas, T. M. et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J. Clin. Oncol. 29, e819\u2013e822 (2011).","journal-title":"J. Clin. Oncol."},{"key":"63091_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000365413","volume":"7","author":"F Aroldi","year":"2014","unstructured":"Aroldi, F. et al. Tyrosine kinase inhibitors in EGFR-mutated large-cell neuroendocrine carcinoma of the lung? A case report. Case Rep. Oncol. 7, 478\u2013483 (2014).","journal-title":"Case Rep. Oncol."},{"key":"63091_CR9","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1097\/JTO.0000000000000103","volume":"9","author":"N Omachi","year":"2014","unstructured":"Omachi, N. et al. A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib. J. Thorac. Oncol. 9, e40\u2013e42 (2014).","journal-title":"J. Thorac. Oncol."},{"key":"63091_CR10","doi-asserted-by":"publisher","first-page":"22028","DOI":"10.18632\/oncotarget.4314","volume":"6","author":"A Karlsson","year":"2015","unstructured":"Karlsson, A. et al. Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget 6, 22028\u201322037 (2015).","journal-title":"Oncotarget"},{"key":"63091_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03099-x","volume":"9","author":"J George","year":"2018","unstructured":"George, J. et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat. Commun. 9, 1048 (2018).","journal-title":"Nat. Commun."},{"key":"63091_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1158\/1078-0432.CCR-17-1921","volume":"24","author":"JL Derks","year":"2018","unstructured":"Derks, J. L. et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin. Cancer Res. 24, 33\u201342 (2018).","journal-title":"Clin. Cancer Res."},{"key":"63091_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1158\/1078-0432.CCR-16-0355","volume":"23","author":"T Miyoshi","year":"2017","unstructured":"Miyoshi, T. et al. Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin. Cancer Res. 23, 757\u2013765 (2017).","journal-title":"Clin. Cancer Res."},{"key":"63091_CR14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1158\/1078-0432.CCR-19-0556","volume":"26","author":"M Zhuo","year":"2020","unstructured":"Zhuo, M. et al. The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. Clin. Cancer Res. 26, 892\u2013901 (2020).","journal-title":"Clin. Cancer Res."},{"key":"63091_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"63091_CR16","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20, 1239\u20131251 (2019).","journal-title":"Lancet Oncol."},{"key":"63091_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1\u201310 (2020).","journal-title":"J. Clin. Oncol."},{"key":"63091_CR18","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"63091_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"63091_CR20","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"63091_CR21","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"63091_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","volume":"18","author":"VK Morris","year":"2017","unstructured":"Morris, V. K. et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 446\u2013453 (2017).","journal-title":"Lancet Oncol."},{"key":"63091_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40425-017-0281-y","volume":"5","author":"VE Wang","year":"2017","unstructured":"Wang, V. E. et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J. Immunother. Cancer 5, 75 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"63091_CR24","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"63091_CR25","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220\u20132229 (2018).","journal-title":"N. Engl. J. Med."},{"key":"63091_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares, L. et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 7, 100408 (2022).","journal-title":"ESMO Open"},{"key":"63091_CR27","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng, Y. et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N. Engl. J. Med. 391, 1313\u20131327 (2024).","journal-title":"N. Engl. J. Med."},{"key":"63091_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.lungcan.2018.12.006","volume":"128","author":"C Mauclet","year":"2019","unstructured":"Mauclet, C. et al. Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab. Lung Cancer 128, 53\u201356 (2019).","journal-title":"Lung Cancer"},{"key":"63091_CR29","doi-asserted-by":"publisher","first-page":"8245","DOI":"10.2147\/OTT.S259893","volume":"13","author":"X Zhang","year":"2020","unstructured":"Zhang, X., Sun, Y., Miao, Y. & Xu, S. Immune checkpoint inhibitor therapy achieved complete response for drug-sensitive EGFR\/ALK mutation-negative metastatic pulmonary large-cell neuroendocrine carcinoma with high tumor mutation burden: a case report. Onco Targets Ther. 13, 8245\u20138250 (2020).","journal-title":"Onco Targets Ther."},{"key":"63091_CR30","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1111\/1759-7714.13471","volume":"11","author":"R Oda","year":"2020","unstructured":"Oda, R. et al. Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab. Thorac. Cancer 11, 2036\u20132039 (2020).","journal-title":"Thorac. Cancer"},{"key":"63091_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.lungcan.2020.03.008","volume":"143","author":"S Sherman","year":"2020","unstructured":"Sherman, S. et al. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer 143, 40\u201346 (2020).","journal-title":"Lung Cancer"},{"key":"63091_CR32","doi-asserted-by":"publisher","unstructured":"Dudnik, E. et al. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. J. Immunother. Cancer 9, https:\/\/doi.org\/10.1136\/jitc-2020-001999 (2021).","DOI":"10.1136\/jitc-2020-001999"},{"key":"63091_CR33","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1158\/1078-0432.CCR-22-1552","volume":"29","author":"DH Owen","year":"2023","unstructured":"Owen, D. H. et al. A phase II clinical trial of nivolumab and temozolomide for neuroendocrine neoplasms. Clin. Cancer Res. 29, 731\u2013741 (2023).","journal-title":"Clin. Cancer Res."},{"key":"63091_CR34","volume":"2","author":"HZ Chen","year":"2021","unstructured":"Chen, H. Z. et al. Genomic and transcriptomic characterization of relapsed SCLC through rapid research autopsy. JTO Clin. Res Rep. 2, 100164 (2021).","journal-title":"JTO Clin. Res Rep."},{"key":"63091_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41568-019-0164-2","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin, C. M. et al. Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat. Rev. Cancer 19, 415 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"63091_CR36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jtho.2020.11.006","volume":"16","author":"TK Owonikoko","year":"2021","unstructured":"Owonikoko, T. K. et al. YAP1 expression in SCLC defines a distinct subtype with T-cell-inflamed phenotype. J. Thorac. Oncol. 16, 464\u2013476 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"63091_CR37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","volume":"176","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell 176, 334\u2013347.e12 (2019).","journal-title":"Cell"},{"key":"63091_CR38","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.1038\/s41586-018-0228-6","volume":"559","author":"Cancer Genome Atlas Research Network","year":"2018","unstructured":"Cancer Genome Atlas Research Network Author Correction: Comprehensive molecular profiling of lung adenocarcinoma. Nature 559, E12 (2018).","journal-title":"Nature"},{"key":"63091_CR39","doi-asserted-by":"publisher","first-page":"72ra17","DOI":"10.1126\/scitranslmed.3001498","volume":"3","author":"B Ateeq","year":"2011","unstructured":"Ateeq, B. et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci. Transl. Med. 3, 72ra17 (2011).","journal-title":"Sci. Transl. Med."},{"key":"63091_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06860-4","volume":"9","author":"F Chen","year":"2018","unstructured":"Chen, F. et al. Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. Nat. Commun. 9, 4315 (2018).","journal-title":"Nat. Commun."},{"key":"63091_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"63091_CR42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"63091_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2022.4933","volume":"9","author":"M Rakaee","year":"2023","unstructured":"Rakaee, M. et al. Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC. JAMA Oncol. 9, 51\u201360 (2023).","journal-title":"JAMA Oncol."},{"key":"63091_CR44","volume":"2","author":"C Agar","year":"2021","unstructured":"Agar, C. et al. Brief report on the efficacy of nivolumab in patients with previously treated advanced large-cell neuroendocrine cancer of the lung. JTO Clin. Res. Rep. 2, 100129 (2021).","journal-title":"JTO Clin. Res. Rep."},{"key":"63091_CR45","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/1541-7786.MCR-08-0567","volume":"7","author":"N Ozaki","year":"2009","unstructured":"Ozaki, N. et al. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol. Cancer Res. 7, 1572\u20131581 (2009).","journal-title":"Mol. Cancer Res."},{"key":"63091_CR46","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/pros.22787","volume":"74","author":"C Wang","year":"2014","unstructured":"Wang, C. et al. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer. Prostate 74, 689\u2013701 (2014).","journal-title":"Prostate"},{"key":"63091_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00305-2","volume":"10","author":"R Tiwari","year":"2021","unstructured":"Tiwari, R. et al. Correction: SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. Oncogenesis 10, 16 (2021).","journal-title":"Oncogenesis"},{"key":"63091_CR48","doi-asserted-by":"publisher","first-page":"F382","DOI":"10.1152\/ajprenal.00357.2012","volume":"305","author":"T Marchbank","year":"2013","unstructured":"Marchbank, T., Mahmood, A. & Playford, R. J. Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2. Am. J. Physiol. Ren. Physiol. 305, F382\u2013F389 (2013).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"63091_CR49","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn, M. J. et al. Tarlatamab for patients with previously treated small-cell lung cancer. N. Engl. J. Med. 389, 2063\u20132075 (2023).","journal-title":"N. Engl. J. Med."},{"key":"63091_CR50","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"MK Baine","year":"2020","unstructured":"Baine, M. K. et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J. Thorac. Oncol. 15, 1823\u20131835 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"63091_CR51","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-23-2360","volume":"30","author":"J Ng","year":"2024","unstructured":"Ng, J. et al. Molecular and pathologic characterization of YAP1-expressing small cell lung cancer cell lines leads to reclassification as SMARCA4-deficient malignancies. Clin. Cancer Res. 30, 1846\u20131858 (2024).","journal-title":"Clin. Cancer Res."},{"key":"63091_CR52","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1158\/1078-0432.CCR-24-0361","volume":"30","author":"CA Stewart","year":"2024","unstructured":"Stewart, C. A. et al. YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities. Clin. Cancer Res. 30, 4743\u20134754 (2024).","journal-title":"Clin. Cancer Res."},{"key":"63091_CR53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi, G. et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr. Pathol. 33, 115\u2013154 (2022).","journal-title":"Endocr. Pathol."},{"key":"63091_CR54","doi-asserted-by":"publisher","unstructured":"Muquith, M. et al. Tissue-specific thresholds of mutation burden associated with anti-PD-1\/L1 therapy benefit and prognosis in microsatellite-stable cancers. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-024-00752-x (2024).","DOI":"10.1038\/s43018-024-00752-x"},{"key":"63091_CR55","doi-asserted-by":"publisher","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017, https:\/\/doi.org\/10.1200\/PO.17.00011 (2017).","DOI":"10.1200\/PO.17.00011"},{"key":"63091_CR56","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","volume":"14","author":"SP Suehnholz","year":"2024","unstructured":"Suehnholz, S. P. et al. Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov. 14, 49\u201365 (2024).","journal-title":"Cancer Discov."},{"key":"63091_CR57","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Committee ALQA. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"63091_CR58","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"63091_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0655-5","volume":"11","author":"F Finotello","year":"2019","unstructured":"Finotello, F. et al. Correction to: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 11, 50 (2019).","journal-title":"Genome Med."},{"key":"63091_CR60","volume":"3","author":"SY Kim","year":"2022","unstructured":"Kim, S. Y. et al. Characterization of MET Exon 14 skipping alterations (in NSCLC) and identification of potential therapeutic targets using whole transcriptome sequencing. JTO Clin. Res Rep. 3, 100381 (2022).","journal-title":"JTO Clin. Res Rep."},{"key":"63091_CR61","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1470-2045(22)00783-5","volume":"24","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet Oncol. 24, 151\u2013161 (2023).","journal-title":"Lancet Oncol."},{"key":"63091_CR62","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63091-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:11:57Z","timestamp":1757409117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63091-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63091"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63091-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6639680\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.H.N.: honoraria: the Korean Society of Medical Oncology, TEMPUS, OncLive, Oklahoma University, Targeted Oncology; travel compensation: Korean Society of Medical Oncology, American Association for Cancer Research; consultation fees: Guidepoint Global, Putnam Associates, Capvision; compensation from Outlier.ai to provide feedback on data analysis tools, AI development; Equity in Revolution Medicine, Summit Therapeutics. M.G.E. receives full-time employment, travel\/speaking expenses, and stock\/stock options from Caris Life Sciences. A.C.C.: advisory boards: AbbVie, Amgen, BI, Merck, Jazz, and Research funding: Zai Labs. D.J.P.: Lecture fees: Bayer Healthcare, AstraZeneca, EISAI, Bristol Myers Squibb, Roche, Ipsen, OncLive; Travel expenses: Bristol Myers Squibb, Roche, Bayer Healthcare; Consulting fees: Mina Therapeutics, Boeringer Ingelheim, Ewopharma, EISAI, Ipsen, Roche, H3B, AstraZeneca, DaVolterra, Starpharma, Boston Scientific, Mursla, Avammune Therapeutics, LiFT Biosciences, Exact Sciences; Research funding (to institution): MSD, BMS, GSK, EISAI. N.A.: No conflicts to declare. P.R. reports travel support from AstraZeneca, MSD, BMS, and Kiowa Kirin outside the submitted work. M.R. received lecture fees from AstraZeneca. F.A.-L.: Research PI (AZ, Alira Health). A.I.V. received consulting honorarium from AstraZeneca, AbbVie, Janssen, Regeneron, Merus, and Novocure. T.A.: Employee of Caris Life Sciences. J.Z. reported the following: Grants\/Contracts: AbbVie, AstraZeneca, BeiGene, BridgeBio, Genentech, Hengrui Therapeutics, InnoCare Pharma, Janssen, Kahr Medical, Merck, Mirati Therapeutics, Nilogen, Novartis, Champions Oncology, BMS. Consulting fees: AstraZeneca, Hengrui Therapeutics, Mirati Therapeutics, Novartis, Novocure, Regeneron, Sanofi, and Takeda Oncology. Payment or honoraria for lectures, presentations, speakers, bureaus, manuscript writing, or educational events: AstraZeneca, MJH Life Sciences, Novartis, Regeneron, Sanofi, and Takeda. A.S.W. has performed consulting work for MJH Life Sciences and received speaking fees from The Binaytara Foundation and Janssen. L.M.: Travel support: BMS. J.B.: grants for consultancies\/advisory boards: BMS, Roche, AstraZeneca. Speaker fees: AstraZeneca, Lilly, Johnson and Johnson. Travel support: Roche, AstraZeneca, MSD, Johnson and Johnson. Research funding (to institution): SEOM. C.G.: grants for consultancies\/advisory boards: MSD, BMS, Oncowissen, AstraZeneca, REGENERON, Roche. Speaker fees: AstraZeneca, Boehringer Ingelheim, Chugai, Pierre-Fabre, MSD, Sanofi\/REGENERON. Writing\/Editorial activity: BMS, MSD. Travel support: Sanofi\/REGENERON, MSD. Research fundings (to institution): BMBF\/Deutsche Krebshilfe\/Deutsche Forschungsgemeinschaft. D.O.: Honorarium: Chugai. Research funding (to institution): Merck, BMS, Palobiofarma, Genentech, AbbVie, Nuvalent, Onc.AI. J.K.H. received consulting honorarium from Jackson Laboratory for Genomic Medicine and ARUP. H.B.: Research Support (Clinical Trials): BMS, Lilly, Amgen; Advisory Board\/Consultant: BMS, Lilly, Genentech, Pfizer, Merck, EMD Serono, Boehringer Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Amgen, Axiom, PharmaMar, Takeda, Mirati, Daiichi, Guardant, Natera, Oncocyte, Beigene, iTEO, Jazz, Janssen, Puma, BerGenBio, Bayer, Iobiotech, Grid Therapeutics, RAPT; Data and Safety Monitoring Board: University of Pennsylvania: CAR T Program, Takeda, Incyte, Novartis, Springworks; Scientific Advisory Board: Sonnetbio (Stock Options); Inspirna (formerly Rgenix, Stock Options); Nucleai (stock options); Honoraria: Amgen, Pfizer, Daiichi, Regeneron; Travel: Amgen, BMS, Merck, Lilly, EMD Serono, Genentech, Regeneron, Mirati. M.D.: Advisory boards; Sanofi\/Genzyme, Regeneron, Janssen, AstraZeneca, Gilead, Bristol Myer Squibb, Catalyst Pharmaceuticals, Novocure, Guardant Consulting: AbbVie, Janssen, Gilead, Daiichi Sankyo, Bristol Myer Squibb Research: Merck, Genentech, CellSight, Novartis, Varian. A.E.: Employee of Caris Life Sciences. J.J.L. has served as a compensated consultant for Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, Bayer, Elevation Oncology, Novartis, Mirati Therapeutics, AnHeart Therapeutics, Takeda, CLaiM Therapeutics, Ellipses, Hyku BioSciences, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Yuhan, Merus, Regeneron, Pfizer, Nuvation Bio, and Turning Point Therapeutics; has received institutional research funds from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche, Linnaeus Therapeutics, Nuvalent, and Novartis; and travel support from Pfizer and Merus. C.K.: Research funding (to institution): AstraZeneca, Novartis, Regeneron, Janssen, Genentech, Lyell, Daiichi Sankyo, Gilead, Macrogenics, Boehringer Ingelheim, Black Diamond Therapeutics. Consulting fees: Arcus, AstraZeneca, Daiichi Sankyo, Eisai, Regeneron, Sanofi, Takeda, J&J, Pinetree, Boehringer Ingelheim, Gencurix. M.N. is on the advisory board for AstraZeneca, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Janssen, Pfizer, Eli Lilly and Company, Bayer, Regeneron, BMS and Genentech; consultant for Caris Life Sciences (virtual tumor board); speaker for Blueprint Medicines, Janssen, Mirati and Takeda; and reports travel support from AnHeart Therapeutics. Reports stock\/stock options from MBrace Therapeutics. T.U.M. currently or has previously served on Advisory and\/or Data Safety Monitoring Boards for Rockefeller University, Regeneron, AbbVie, Merck, EMD Serono, Storm, Geneos, Bristol-Meyers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, DrenBio, Glenmark, Simcere, Arrowhead, Surface\/Coherus, G1 Therapeutics, NGMbio, DBV Technologies, Arcus, Fate, Ono, Storm, Replimmune, Larkspur, Avammune, and Astellas, and has research grants from the National Institutes of Health (NCI), the Cancer Research Institute, Regeneron, Genentech, Bristol Myers Squibb, Merck, and Boehringer Ingelheim. A.R.N. reports: Funding to Institution for Trials he is PI on: Loxo@Lilly, Surface Oncology, ADC Therapeutics, IGM Biosciences, EMD Serono, Aravive, Nikang Therapeutics, Inspirna, Exelexis, Revolution Medicine, Jacobio, Pionyr, Jazz Pharmaceuticals, NGM Biopharmaceuticals, Immunocore, Phanes Therapeutics, Kymera Therapeutics, Dren Bio, Daichi; Consultant Editor Compensation: JCO Precision Oncology; Travel Compensation from: SITC\/ AACR\/ Conquer Cancer Foundation\/BinayTara Foundation and Foundation Med\/ Caris Life Sciences\/ ASCO; Advisory Board: Foundation Med, Astellas, NGM\u00a0biosciences, Natera, Regeneron; Honoraria: BinayTara Foundation, Foundation Med, Medlive; Grant Support: SOWG Hope Foundation. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7717"}}